Month: September 2024

Aspa Therapeutics: A Study of AAV9 Gene Therapy in Children With Canavan Disease

Clinical Trials / November 25, 2024

Aspa Therapeutics: A Study of AAV9 Gene Therapy in Children With Canavan Disease (CANaspire Clinical Trial) [https://treatcanavan.com/canaspire-trial/]   Aspa’s investigational gene therapy trial uses an AAV9 vector (adeno-associated virus serotype 9), which is designed to deliver functional copies of the ASPA gene throughout the body, including into the brain, to address the underlying cause of Canavan disease. The AAV9 …

Aspa Therapeutics: A Study of AAV9 Gene Therapy in Children With Canavan Disease Read More »

Aspa Therapeutics: A Natural History Study of Patients With Canavan Disease

News / September 24, 2024

Aspa Therapeutics: A Natural History Study of Patients With Canavan Disease (CANinform Study) [https://clinicaltrials.gov/study/NCT04126005] CANinform is a natural history study of patients with Canavan disease that will help researchers better understand the disease and provide a foundation for Aspa’s gene therapy program. The study is open to individuals with a confirmed diagnosis of Canavan disease.

BridgeBio press release about the RMAT designation for the Aspa clinical trial in Canavan Disease

News / September 16, 2024

09.10.2024 at 4:45 PM EDT – Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812 has potential to address the unmet needs of individuals with Canavan disease – BridgeBio will leverage the benefits of RMAT designation, …

BridgeBio press release about the RMAT designation for the Aspa clinical trial in Canavan Disease Read More »